Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS)
CNY 30.73
(0.33%)
CNY 30.73
(0.33%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.11 Billion CNY | -4.6% |
| 2022 | 1.17 Billion CNY | 14.43% |
| 2021 | 1.02 Billion CNY | 10.96% |
| 2020 | 921.91 Million CNY | -2.67% |
| 2019 | 947.23 Million CNY | 23.22% |
| 2018 | 768.75 Million CNY | 61.39% |
| 2017 | 476.33 Million CNY | 40.59% |
| 2016 | 338.8 Million CNY | 40.75% |
| 2015 | 240.71 Million CNY | 15.32% |
| 2014 | 208.74 Million CNY | 28.46% |
| 2013 | 162.49 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 314.99 Million CNY | 18.04% |
| 2024 Q2 | 349.1 Million CNY | 10.83% |
| 2024 Q3 | 370.42 Million CNY | 6.11% |
| 2023 Q4 | 266.85 Million CNY | -9.36% |
| 2023 FY | 1.11 Billion CNY | -4.6% |
| 2023 Q3 | 294.42 Million CNY | 6.1% |
| 2023 Q2 | 277.5 Million CNY | -0.13% |
| 2023 Q1 | 277.85 Million CNY | 1.81% |
| 2022 Q2 | 306.45 Million CNY | 13.94% |
| 2022 Q1 | 268.95 Million CNY | 7.8% |
| 2022 FY | 1.17 Billion CNY | 14.43% |
| 2022 Q4 | 272.92 Million CNY | -15.29% |
| 2022 Q3 | 322.17 Million CNY | 5.13% |
| 2021 Q2 | 277.45 Million CNY | 25.4% |
| 2021 Q1 | 221.24 Million CNY | -11.2% |
| 2021 FY | 1.02 Billion CNY | 10.96% |
| 2021 Q3 | 274.73 Million CNY | -0.98% |
| 2021 Q4 | 249.49 Million CNY | -9.19% |
| 2020 FY | 921.91 Million CNY | -2.67% |
| 2020 Q1 | 176.41 Million CNY | -34.43% |
| 2020 Q2 | 258.55 Million CNY | 46.56% |
| 2020 Q3 | 237.79 Million CNY | -8.03% |
| 2020 Q4 | 249.16 Million CNY | 4.78% |
| 2019 Q3 | 202.87 Million CNY | -23.29% |
| 2019 Q2 | 264.47 Million CNY | 25.43% |
| 2019 Q1 | 210.85 Million CNY | 0.0% |
| 2019 FY | 947.23 Million CNY | 23.22% |
| 2019 Q4 | 269.03 Million CNY | 32.61% |
| 2018 FY | 768.75 Million CNY | 61.39% |
| 2017 FY | 476.33 Million CNY | 40.59% |
| 2016 FY | 338.8 Million CNY | 40.75% |
| 2016 Q1 | 60.81 Million CNY | 0.89% |
| 2016 Q2 | 60.81 Million CNY | 0.0% |
| 2015 Q2 | 56.08 Million CNY | 0.0% |
| 2015 Q1 | 56.08 Million CNY | 0.0% |
| 2015 Q4 | 60.28 Million CNY | 0.0% |
| 2015 FY | 240.71 Million CNY | 15.32% |
| 2014 FY | 208.74 Million CNY | 28.46% |
| 2013 FY | 162.49 Million CNY | 0.0% |